Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer

被引：0
|
作者：
Liu, Renyan [1 ]
Pantelidou, Constantia [1 ]
Jadhav, Heta [1 ]
Shapiro, Geoffrey [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5649
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6
    Gong, Xuegian
    Chio, Li -Chun
    Lallena, MaryJo
    Merzoug, Farhana
    Chu, Shaoyou
    Webster, Yue
    Dempsey, Jack
    Ma, Xiwen
    De Dios, Alfonso
    Beckman, Richard
    Buchanan, Sean G.
    CANCER RESEARCH, 2015, 75
  • [42] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
    Formisano, Luigi
    Lu, Yao
    Servetto, Alberto
    Hanker, Ariella B.
    Jansen, Valerie M.
    Bauer, Joshua A.
    Sudhan, Dhivya R.
    Guerrero-Zotano, Angel L.
    Croessmann, Sarah
    Guo, Yan
    Ericsson, Paula Gonzalez
    Lee, Kyung-Min
    Nixon, Mellissa J.
    Schwarz, Luis J.
    Sanders, Melinda E.
    Dugger, Teresa C.
    Cruz, Marcelo Rocha
    Behdad, Amir
    Cristofanilli, Massimo
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Nagy, Rebecca J.
    Lanman, Richard B.
    Solovieff, Nadia
    He, Wei
    Miller, Michelle
    Su, Fei
    Shyr, Yu
    Mayer, Ingrid A.
    Balko, Justin M.
    Arteaga, Carlos L.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [43] CDK6 might be a key factor for efficacy of CDK4/6 inhibitor and the hormone sensitivity following acquired resistance
    Iida, Masafumi
    Nakamura, Misato
    Tokuda, Emi
    Niwa, Toshifumi
    Ishida, Takanori
    Hayashi, Shin-ichi
    CANCER RESEARCH, 2018, 78 (04)
  • [44] Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
    Raub, Thomas J.
    Wishart, Graham N.
    Kulanthaivel, Palaniappan
    Staton, Brian A.
    Ajamie, Rose T.
    Sawada, Geri A.
    Gelbert, Lawrence M.
    Shannon, Harlan E.
    Sanchez-Martinez, Concepcion
    De Dios, Alfonso
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (09) : 1360 - 1371
  • [45] Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER plus breast cancer
    Mavrommati, Ioanna
    Moughari, Fatemeh Ahmadi
    Thakur, Shefali
    Zhang, Yu
    Martin, Lesley-Ann
    Haider, Syed
    Natrajan, Rachael
    CANCER RESEARCH, 2024, 84 (03)
  • [46] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [47] Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
    Glaviano, Antonino
    Wander, Seth A.
    Baird, Richard D.
    Yap, Kenneth C. -H.
    Lam, Hiu Yan
    Toi, Masakazu
    Carbone, Daniela
    Geoerger, Birgit
    Serra, Violeta
    Jones, Robert H.
    Ngeow, Joanne
    Toska, Eneda
    Stebbing, Justin
    Crasta, Karen
    Finn, Richard S.
    Diana, Patrizia
    Vuina, Karla
    de Bruin, Robertus A. M.
    Surana, Uttam
    Bardia, Aditya
    Kumar, Alan Prem
    DRUG RESISTANCE UPDATES, 2024, 76
  • [48] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [49] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
    Owsley, J.
    Jimeno, A.
    Diamond, J. R.
    DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
  • [50] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
12345